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Promoting Antibiotic Stewardship in Primary Care Setting: An Evaluation Process of
Treatment Practices for Uncomplicated Urinary Tract Infections in Premenopausal NonPregnant Women
Abstract
Problem
Inappropriate antibiotic prescribing increases the prevalence of antibiotic resistance. While
evidence-based practice guidelines can reduce antibiotic use, inconsistent adherence to these
guidelines results in ineffective treatment, increased cost, and increasing antibiotic resistance.
Context
At Athena Med-Monterey, a multi-provider primary care clinic where approximately 90% of the
patients are women, written guidelines for uncomplicated urinary tract infections (uUTIs) in
premenopausal non-pregnant women (PrMNPW) are lacking. In addition, there are no processes
for assessing adherence to clinical guidelines.
Interventions
The advanced practice nurse (APN) led a quality improvement process to assess and promote
adherence to practice guidelines using a small test of change and the plan-do-study-act (PDSA)
method. Qualitative assessment and retrospective chart review were performed to measure
outcomes.
Measures

6
This project examined the clinicians’ adherence to evidenced-based guidelines and use of firstline agents to treat uUTIs in PrMNPW, and evaluated opportunities for ongoing practice
improvement in treating uUTIs and adherence to clinical practice guidelines.
Results
The quality improvement process successfully evaluated and promoted adherence to evidencebased practice guidelines. Both the qualitative assessment and retrospective chart reviews found
that the clinicians used evidence-based guidelines and first-line agents to treat uUTIs in
PrMNPW. No practice improvement intervention was needed for antibiotic treatment of this
specific condition.
Conclusions
The clinicians’ adherence to the guidelines yielded desired practice and patient outcomes. The
APN-driven small test of change and PDSA method demonstrated success in implementing a
process to evaluate and promote evidence-based guidelines and first-line agents to treat
infections in primary care.
Keywords: small test of change, plan-do-study-act, uncomplicated urinary tract
infections, premenopausal non-pregnant women, adherence to first-line agents
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Promoting Antibiotic Stewardship in Primary Care Setting: An Evaluation Process of
Treatment Practices for Uncomplicated Urinary Tract Infections in Premenopausal NonPregnant Women
Background
Antibiotic resistance leads to approximately 2.8 million infections and 35,000 deaths per
year in the United States. Growth of pathogens resistant to first-line agents can require
management with expensive and toxic alternative agents, leading to increased antibiotic-resistant
conditions and death rate. Inappropriate antibiotic prescribing in primary health care setting is
the foremost modifiable risk factor for antibiotic resistance (CDC, 2021). While, antibiotic
stewardship requires adherence to evidence-based recommendations for diagnosis and
management, outpatient stewardship efforts could improve antibiotic prescribing practices and
clinical outcomes (Sanchez, et al., 2016).
Problem Description
Urinary tract infections (UTIs) are the most common outpatient infection in primary
healthcare, generating an overall annual cost of $1.6 billion in the United States (Medina &
Castillo-Pino, 2019). UTIs are prevalent in women 14–24 years old, and more than half of all
adult women will have at least one UTI in their lifetime. The unnecessary use of antibiotics for
treating such infections contributes to the increasing national and global prevalence of antibiotic
resistance (Llor & Bjerrum, 2014). While practice guidelines and other research studies have
aimed to reduce antibiotic use, few primary care providers (PCPs) rely directly on these
guidelines to treat uncomplicated UTIs (Grigoryan et al., 2019).
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In 2011, the International Clinical Practice Guidelines for the Treatment of Acute
Uncomplicated Cystitis (AUC) and Pyelonephritis in Pre-Menopausal Non-Pregnant Women
(PrMNPW) were published by the Infectious Diseases Society of America (IDSA) and the
European Society for Microbiology and Infectious Diseases (Gupta et al., 2011). These
guidelines were released to decrease the occurrence of treatment-resistant uropathogens.
According to the guideline, women who have dysuria with no complicating features can be
treated for cystitis without any further diagnostic evaluation (Michels & Sands, 2015). Regarding
acute pyelonephritis, the 2011 IDSA guidelines emphasized treatment with oral ciprofloxacin,
levofloxacin, or sulfamethoxazole-trimethoprim (SMX-TMP) appropriately tailored to the
patient’s urine culture and susceptibility test results.
Setting
Athena Med-Monterey (Athena Healthcare Systems, 2020) is a multi-practice
clinic with multiple providers who are experts in their fields (including obstetrics and
gynecology, internal medicine, occupational medicine, and advanced practice nursing).
About 90% of patients seen in the clinic are women. Women who present with UTI
symptoms are prescribed antibiotics, either at the initial visit or after t wo days, when the
urine culture and sensitivity results are available. If available, the clinicians refer to the urine
culture results to confirm the antibiotic chosen for UTI treatment. To meet and quantify the
organization’s goal of efficient and timely treatment, the clinic could use quality
measurement tools or evaluation processes to measure practices and outcomes. This action plan
would ensure use of practice guidelines for consistency of care and provide decisive
recommendations that would reassure clinicians of the appropriateness of the planned treatment
(Woolf et al., 1999).
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Specific Aims
The overarching goal of this project was to improve patient outcomes by promoting
practice improvement in primary healthcare, specifically adherence to evidenced-based clinical
practice guidelines in antibiotic prescribing. The project evaluated the opportunities for practice
improvement in the treatment of uUTI. The process of small test of change and PDSA method
was developed for continuous evaluation and promotion of adherence to clinical practice
guidelines. This project examined Athena Med-Monterey’s multi-provider primary clinic’s
adherence to following evidenced-based guidelines, such as the 2011 IDSA guidelines, to treat
PrMNPW presenting with symptoms of uUTI.
The overall goal of the proposed project was to design and implement a process for
evaluating and supporting adherence to evidenced-based clinical practice guidelines. This project
focused on using this process to promote prescription of first-line agents for treating uUTIs (as
determined by clinical practice guidelines), a process that could be used in the future to evaluate
adherence to other antibiotic prescribing guidelines. The 2011 IDSA guidelines are an
evidenced-based tool that clinicians in primary healthcare should reference when treating uUTIs.
The following objectives were used in the development of a process for evaluating and
promoting adherence to clinical practice guidelines:
1. Perform a provider-led small test of change using the PDSA method and the 2011 IDSA
guidelines to establish clinical guidelines for treating uUTIs in PrMNPW.
2. Evaluate clinicians’ adherence to use of evidence-based guidelines and first-line agents
for treating uUTIs in PrMNPW, utilizing the small test of change and PDSA processes.
3. Measure symptom resolution at 28 days post-uUTI treatment to evaluate the treatment
efficacy.
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4. If applicable, integrate the 2011 IDSA guidelines into the clinic’s current clinical
practices for treating uUTIs in PrMNPW.
5. Provide evaluation feedback to the clinic leadership.
Available Knowledge
PICOT Question
The PICOT question that guided this project is: Does primary healthcare clinicians’ (P)
adherence to utilization of evidenced-based clinical practice guidelines (I) improve patient
outcomes (O), compared with treatment without the use of clinical practice guidelines (C), over 4
weeks of small test of change (T)? State authorized prescribing clinicians in primary healthcare
is the population of interest in this project. The use and availability of evidence-based clinical
practice guidelines (vs. no use of clinical practice guidelines) increase adherence to prescribing
first-line agents for treating uUTIs in PrMNPW and yield desired outcomes in terms of symptom
resolution and cost-effectiveness. This literature reviewed for this project sought to evaluate
whether provider adherence to evidenced-based clinical guidelines has improved since the 2017
Centers for Disease Control and Prevention (CDC) guidelines for treating uUTIs were released
(Table 1). The literature review also examined whether integrating the 2011 IDSA guidelines
into multi-provider primary care organizations increases adherence to the prescription of firstline agents and thereby improves the quality of clinical decisions and patient outcomes.
Search Strategy
The literature review was conducted in compliance with the Preferred Reporting Items
for Systematic Reviews and Meta-Analysis (PRISMA), and a systematic search for articles was
conducted in the PubMed and Cochrane search engines using Boolean operators (AND, OR).
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The inclusion criteria were articles that were published between 2017 and 2020, had text in
English, and were peer-reviewed. The search terms “first-line antibiotics AND acute
uncomplicated cystitis OR uncomplicated urinary tract infection” AND “prescription adherence
AND first-line antibiotics AND acute uncomplicated cystitis OR uncomplicated urinary tract
infection” were used initially. The search terms were then modified to “outcomes AND first-line
antibiotics AND acute uncomplicated cystitis OR uncomplicated urinary tract infection.” The
search resulted in 15 publications from 2017–2020 from both the PubMed and Cochrane
databases. Additional search terms were “nitrofurantoin AND cystitis,” “fosfomycin AND
cystitis,” and “sulfamethoxazole-trimethoprim AND cystitis.” Of the 15 publications, five aimed
to evaluate prescriber adherence to the guidelines for treating uUTIs (Diagram 1).
Integrated Review of the Literature
Robinson et al. (2019) evaluated the appropriateness of empiric fluoroquinolone (FQ) use
compared to nitrofurantoin (NTF) use for treating AUC and determined the trends and predictors
for using FQ. Women aged 19–64 who were given NTF, ciprofloxacin, or levofloxacin for AUC
at five family medicine clinics were included in the study. Data regarding symptoms,
comorbidities, allergies, creatinine clearance, recent antibiotic use, and urine cultures were used
to determine whether empiric antibiotic treatment was appropriate based on national guidelines
and local susceptibility data. Of the 567 women included in the study, 395 were given NTF, and
172 were given FQ. Of these, 343 (86.8%) and 18 (10.5%) were appropriately prescribed NTF
and FQ, respectively. Of the women inappropriately prescribed FQ, 15 (87.8%) lacked
contraindication to NTF. Therefore, the study suggested the need for additional intervention and
education to improve and decrease the use of FQ.
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Yu et al. (2020) aimed to track and report outpatient antibiotic prescriptions in Medicare
Part B older adult enrollees who were diagnosed with cystitis in an outpatient setting between
2016 and 2017 in New York State (NYS). The inclusion criteria included an oral antibiotic
prescription given less than three days after diagnosis of cystitis in Part D claims. According to
the retrospective cohort study, 50,658 prescriptions were written upon discharge diagnosis of
cystitis in NYS from 2016–2017. First-line antibiotic prescriptions of NTF, SMX-TMP, and
fosfomycin (FM), as well as β-lactamase, increased, while FQ use decreased in both older female
and male adults. The study suggested that the widespread prevalence of FQ and β-lactamase
prescriptions requires outpatient antimicrobial stewardship.
Giancola et al. (2019) conducted a quasi-experimental study that included women aged
18–64 who were prescribed NTF, SMX-TMP, or ciprofloxacin within seven days of encounter at
five family medicine clinics. Adherence to duration of treatment (DOT) based on the 2011 IDSA
guidelines was evaluated. A stewardship intervention included revising/adding default
prescription instructions to targeted antimicrobials in an EHR and performing a one-day inservice at two (intervention group) of the five clinics. A total of 787 pre-intervention patients
were compared to 862 post-intervention patients. After the intervention, the adherence rate to the
recommended DOT increased from 31–89% for NTF and from 22–60% for SMX-TMP.
Additionally, adherence to the recommended DOT increased in clinics that received education
(33.7% vs. 90.2%; p < 0.01); these clinics’ adherence increased from 22.1–58.8% (p < 0.01).
Revising/adding default prescription instructions and DOT to targeted antimicrobials in an EHR
and providing a clinician in-service also increased adherence to first-line antibiotic DOT
guidelines.
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Pedela et al. (2017) evaluated changes in outpatient FQ and NTF use and resistance
among E. coli isolates after a change in institutional guidelines that stipulated the use of NTF
instead of FQ to treat AUC. The study compared the period from January 2003 to June 2007,
when FQ was recommended as a first-line therapy for acute uUTIs, with the period from July
2007 to December 2012, when NTF was recommended as the first-line therapy. The
retrospective time series study included 5,714 adults treated for AUC and 11,367 outpatient E.
coli isolates. After the change in institutional guidelines, FQ use showed an immediate 26%
reduction, and FQ-resistant E. coli were stabilized. The use of NTF increased without changing
NTF resistance.
To identify the sources of information that guide antibiotic prescription decisions,
Grigoryan et al. (2019) sought to understand why PCPs choose certain antibiotics or DOT. The
study conducted a semi-structured interview with 18 PCPs in two family medicine clinics in
Texas. Most PCPs reported that they prescribed SMX-TMP or NTF, but sometimes for a longer
duration than recommended by the IDSA (2011). The PCPs also described multiple
considerations when prescribing antibiotics, including allergies, sex, pregnancy, older age, past
antibiotic experience and susceptibilities, familiarity with the antibiotic, shorter treatment
duration and better compliance, UTI frequency, diabetes, and cost. Many PCPs mentioned that
NTF was not as “strong” or as “quick” as SMX-TMP, and most were unfamiliar with FM. Few
PCPs relied directly on guidelines to treat uUTIs; only two recalled and mentioned the 2011
IDSA guidelines. Additionally, the PCPs had widely differing opinions on the extent to which
antibiotic resistance was a problem in their practice.
Summary of Evidence
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Evidence-based, multidisciplinary clinical guidelines are clear, reproducible, and flexible,
and they assist clinicians in making decisions about appropriate healthcare for specific clinical
circumstances (Field & Lohr, 1990). Trials, systematic reviews, and meta-analyses conducted
after the CDC’s 2017 review of the 2011 IDSA guidelines (Table 2) found that clinicians who
referenced these guidelines to manage uUTIs were most likely to achieve positive outcomes. The
use and availability of evidence-based clinical practice guidelines (vs. no use of clinical practice
guidelines) increased adherence to prescribing first-line agents for treating uUTIs in PrMNPW
and yielded desired outcomes in terms of bacterial resolution and cost-effectiveness. The
research in this literature review supports the potential efficacy of the 2011 IDSA guidelines into
Athena Med-Monterey’s current uUTI management practices to potentially increase adherence to
prescribing first-line agents for treating uUTIs in PrMNPW and improve the quality of clinical
decisions and patient outcomes. The literature also supports the usefulness of implementing a
process to evaluate and support clinicians’ adherence to antibiotic prescribing clinical practice
guidelines for other infectious conditions in primary care.
Rationale
Theoretical Framework
The transtheoretical model (TTM) was used to predict and guide behavior changes
among prescribing clinicians. This model elucidated how prescribing clinicians changed their
behaviors at different stages of readiness to improve the quality of practice when treating uUTIs.
People are at different stages of readiness when making health behavior changes, and analyses of
the processes of change can help identify strategies for overcoming particular barriers to
behavioral change (Glanz et al., 2015). If the perceived barriers are greater than the perceived
benefits, the likelihood of behavior change decreases.
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The TTM was augmented with the diffusion of innovations model, which focuses on the
role of change agents in disseminating health interventions. Key constructs to behavior changes
included the extent of effectiveness, cost (i.e., perceived cost, time, and effort), simplicity (i.e.,
ease of understanding), compatibility (i.e., fit with the intended audience), observability (i.e.,
observable outcomes), and trialability (i.e., the extent to which the innovation can be tried before
commitment to change; Oldenburg & Glanz, 2008).
Strong motivation is also needed to yield behavior change in different settings and
populations (Webb & Sheeran, 2006); the motivation to improve and evaluate current practice
triggers behavioral changes. In the present project, the medical director and the director of allied
education agreed (motivation) to set evidence-based clinical guidelines for quality practice
improvement and outcomes (perceived benefit) and therefore approved the proposal. The clinic’s
advanced practice nurse (APN) and the advanced practice nurse student (APNS; i.e., the change
agents) were assigned responsibility for this project. After project approval, the change agents
developed strategies to reduce restraining forces (barriers); these barriers included loss of patient
time, use of break hours for training, and worries about the complexity of the change. Short,
face-to-face change agents’ meetings were held during break times over food or snacks. The
APNS was given safe and remote access to patients’ EHRs, from which the student collected
data for review.
Methods

Context

Athena Health strives to provide the highest quality of care and customer service
to residents and their families through best practices, highly trained staff, and
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innovative programs and services designed to meet patients’ needs (Athena Healthcare
Systems, 2020). As mentioned above, Athena Med-Monterey is a multi-practice clinic
with multiple providers who are experts in their fields (these include obstetrics and
gynecology, internal medicine, occupational medicine, and advanced practice nursing).
Patients presenting with UTI symptoms are prescribed antibiotics, either at the initial
visit or after two days, once urine culture and sensitivity results are available.

Intervention

The PDSA method was used to guide the small test of change that aimed to
measure practice outcomes and set the clinic’s evidenced-based uUTI treatment
guidelines. This shorthand cycle was conducted in the initial phase of the three-year proposed
intervention, from October 21, 2020, through January 4, 2021. A small test of change using the
PDSA is an action-oriented method of testing a change by planning the change, trying it,
observing the results, and acting on what is learned (Institute for Healthcare Improvement,
2020). Within the time allotted for the small test of change, the PDSA method was
conducted in cycles as needed in the hope that the proposed changes led to the desired
improvement. Project roles, communication delivery, and deliverables were clearly stated
and followed.

The small test of change, which was guided by the plan-do-study-act (PDSA) method,
was utilized because of its simplicity, fit, observability, and trialability. In the present project, the
plan was to review practice, integrate the 2011 IDSA uUTI guidelines, and set the clinic’s
treatment guidelines for treating uUTI. The change agents conducted (do) the qualitative
assessment and the retrospective chart review. The current practices were also reviewed against
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the 2011 IDSA treatment guidelines. Analyses (study) of the assessment results, as well as chart
reviews and quality measurement, were used to determine an action. The change agents decided
whether to adapt, adopt, or abandon (act) the plan for establishing clinical treatment guidelines
for uUTI. The stages of behavior change were also observed and identified during this initial
phase of the three-year proposal.

Gap Analysis
Although the patients’ treatment plans for uUTIs are clearly written in their EHRs,
the clinic has no written clinical guidelines that reference evidence -based treatment
guidelines such as the 2011 IDSA guidelines. Furthermore, the quality measurements for
evaluating the treatment outcomes and clinical practices for treating uUTIs are currently
not available (Table 2). Thus, inconsistencies could exist among the clinicians in the
management and prescribing of antibiotics to treat uUTIs in PrMNPW. In addition, there are
no supporting data available to indicate the clinic’s adherence to evidence -based clinical
guidelines for the treatment of uUTIs, no supporting data to indicate the clinic’s
adherence to prescribing first-line agents for uUTI, and no data available to quantify
symptom resolution post treatments. Having written evidence-based treatment guidelines
for uUTIs in PrMNPW could promote the adherence to these guidelines and support
clinicians to consistently follow them and prescribe the defined first-line agents. Using
real-time interoperable EHRs with electronic charting and prescription capabilities could
likely influence this quality practice improvement. Further, continuous electronic
monitoring could be performed using the clinic’s EHRs. The practice outcomes that the
clinic could measure include adhering to the use of evidence-based practices and

18
prescribing first-line agents for the treatment of uUTI and not performing a urine culture
when treating AUC. Furthermore, the additional treatment outcomes that the clinic could
measure include symptom resolution at 28 days after the uUTI treatment.

Gantt Chart
After approval (Letter 1) was obtained from the clinic’s allied health education
director in October 2020, two small tests of practice change or improvement were
attempted during the initial phase of the three-year project timeline (Table 3). The APN
and the APNS formed a team and were assigned as the change agents to lead the small
test of change. The qualitative assessment survey and retrospective review of the records
were performed in October 2020. The records of women aged 18–50 with symptoms of
uUTI (dysuria and frequency of urination) were collected for review. The clinicians’
references for treatment practices and adherence to prescribing first-line agents for
treating uUTIs in PrMNPW were also reviewed in accordance with the 2011 IDSA
evidence-based guidelines. During this initial phase, the attempt to establish clinic
guidelines was abandoned, as the investigation found that the clinicians used resources
that were based on the 2011 IDSA guidelines. Therefore, no practice changes were
proposed. Then, the aspects of the clinicians’ adherence to prescribing first-line agents
for treating uUTIs in PrMNPW as well as symptom resolution within 28 days post
treatment were measured. The first phase was completed on January 1, 2021.
The subsequent chart review was completed, and the second attempt at proposing
practice changes or improvements was identified on January 7, 2021. The second small
test of change aimed to get clinicians to prescribe a first-line agent without performing a
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urine culture for treating AUC. The 2011 IDSA and 2017 CDC guidelines do not
recommend performing a urine culture for the treatment of AUC. This second small test
of change was carried out from February 9, 2021 to February 20, 2021. A preimplementation clinician survey and a short face-to-face project review were conducted a
week prior to commencing the second small test of change.

This second attempt at practice improvement was not completed due to having
limited access to EHRs. The planned intervention for this second attempt at practice
improvement would have been as follows. Upon the acknowledgement of the uUTI
symptoms being the patient’s chief complaint, the scheduling medical assistant would
have added the following urine culture smart phrase to the problem alert box (Fig. 1):
“Urine culture is not recommended for managing acute uncomplicated cystitis in non pregnant premenopausal women. However, for acute pyelonephritis and any type of
complicated UTIs, a urine culture should be obtained before empiric therapy. Consider
pyelonephritis or complicated UTI in the presence of fever, flank pain, and/or nausea and
vomiting.”

Work Breakdown Structure

The director of allied health education represents the clinic’s leadership and was
informed and consulted throughout the project’s initial phase. The APN and the APNS
are the change agents and were responsible for completing the project’s tasks. The tasks
included performing a review of the clinic’s current uUTI practices in comparison with
the 2011 IDSA guidelines, completing the qualitative assessment and retrospective chart
review, analyzing and reporting the outcomes obtained, and presenting recommendations
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to the director of allied health education. The director of allied health education and the
change agents interpreted the findings and outcomes and made the decision to abandon
the proposed practice improvement. In addition, the clinicians were informed of the
evaluation process and participated in the qualitative assessment (Table 4).

Responsibility/Communication Matrix

The short face-to-face meetings between the change agent/s and the director of
allied health education were held in an office during break times, over food, or after the
last patients are seen on Wednesdays. The meeting agendas included discussing the plan
and action items as well as the outcomes evaluation and analyses. The project updates
and decisions produced during these meetings were recorded on paper by the APNS. The
qualitative assessment and the remote electronic retrospective chart review were
performed by the APNS, and the findings of these were reported by the APNS to the
clinic leadership twice a month during the face-to-face meetings or through the
University of San Francisco email system (Table 5).

SWOT Analysis

It is evident that the clinic has two strengths (S) with regard to quality practice and
treatment outcomes. They are the real-time interoperable EHRs and the effective
collaborations among clinicians. The electronic charting and prescription capabilities
likely influenced the quality of the practices and treatment outcomes, with easily
accessible electronic resource applications such as UpToDate, Medscape, Epoc rates, and
the CDC guidelines. Patients’ treatment plans are clearly written in their EHRs, and the
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collaborations between clinicians are recorded through the clinic’s secure email and
phone system for when questions regarding patient care arise. In addition, 75% of the
clinicians are obstetricians and gynecologists. Their expert opinions are highly sought out
in the clinic, the patient population of which is 90% women. The opportunities (O) for
quality practice and treatment outcomes include establishing a culture that is supportive
of practice changes and the existence of allied health education that accommodates
students for health professional development. The weaknesses (W) include the
unavailability of antibiograms, or records of local antibiotic resistance patterns, and the
unavailability of continuous quality improvement tools. The constraints in the clinicians’
time and schedule could be considered threats (T) to quality practice and treatment
outcomes (Figure 2).

Budget

The first phase of the small tests of change did not have a negative financial impact. The
estimated total budget for the three-year program was $8,015 (Table 6). An estimated $5,000
was spent on data collection and analysis, and $3,000 was spent on meetings, trainings, and
collaborations. About $15.00 was used to copy papers and purchase office supplies; however, the
clinic had the office supplies and devices to meet these needs. Funds for this budget were taken
from the clinic’s quality improvement and staff education and training funds.
The clinicians’ offices were conducive for one-on-one in-service that maintained six feet
of safe distance, given the COVID-19 pandemic precautions. The APNS was given remote EHR
access and performed safe retrospective chart review of records. As previously mentioned, the
clinic was equipped with interoperable EHR with real-time patient data and electronic charting
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and prescription capabilities. The use of the clinic’s EHR incurred no additional expenses and
most likely influenced this quality practice improvement.

The estimated return of investment for prescribing first-line agents when treating uUTIs
was no recurrence or no return visit within 28 days post-treatment. The individual cost of UTI
recurrence work-up ranges from $390–730 per individual (Gaitonde et. al, 2019). The clinic saw
an average of eight cases of uUTI in two months; therefore, the savings were estimated to be
$3,120–5,840 per patient with no recurrences at 28 days post-treatment. Additionally, not
performing urine cultures for AUC eliminates additional documentation and follow-up calls for
patient notification. If a clinician, with a salary of $100/hour, spent approximately 10 minutes
calling and notifying a patient of a normal urine culture, the clinic could save approximately
$800 per year by not performing urine cultures for AUC.

Study of the Intervention

A retrospective chart review was performed to collect and use data to evaluate
clinicians’ adherence to current evidence-based guidelines, such as the 2011 IDSA
guidelines, when treating uUTI in PrMNPW. Additionally, structured qualitative surveys
were conducted prior to each small test of change. The first survey (Deliverable 1)
evaluated clinicians’ referencing of evidenced-based practice guidelines and their use of
first-line agents for treating uUTI. The second survey (Deliverable 2) evaluated
clinicians’ decisions to order urine cultures for AUC. Analyses of these data were used to
guide proposed plans for practice improvements.
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Post-implementation surveys were intended to measure the practice improvement
outcomes when an intervention occurred. However, analysis of both the initial qualitative
survey and retrospective chart review found that clinicians adhered to the 2011 IDSA
guidelines and prescribed first-line and alternative agents when treating uUTI in
PrMNPW. Thus, the first planned intervention to establish clinic guidelines was
abandoned. Furthermore, limited access to EHRs led to unmeasurable outcomes for the
second planned intervention for practice improvement, which was a small test of change
regarding not performing a urine culture when treating AUC.

Outcome Measures

A completed cycle of the small test of change, guided by the PDSA method, is
considered a successful practice and treatment outcome evaluation process. That is, a
practice change was planned, tried on a small scale, studied, and an acted upon (whether
to adopt, adapt, or abandon the planned practice change). Two primary outcome
measurements were proposed to measure adherence to the guidelines. The first primary
outcome involved the use of evidence-based clinical practice guidelines for treating uUTI
in PrMNPW. The second primary outcome is adherence to prescribing the first-line
agents NTF, SMX-TMP, or FM as opposed to prescribing FQ or β-lactams. Clinicians
achieved adherence if a first-line antibiotic was not prescribed in the absence of
contraindication showing that the patient did not meet the criteria for receiving first-line
antibiotic treatment. The proposed secondary outcome measurement was symptom
resolution. Absence of recurrences or return visits for the same uUTI symptoms within 28
days post-treatment was considered symptom resolution. Furthermore, not performing a
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urine culture when treating AUC was considered adherence to evidenced-based
guidelines. However, as previously mentioned, limited EHR access did not allow for this
small test of practice change.

CQI Method
The PDSA method guided the small test of change (Fig. 3). The evaluation of clinicians’
adherence to evidence-based clinical practice guidelines for the treatment of uUTI in PrMNPW
was successfully completed using the small test of change process in the first phase of the threeyear proposed intervention. Two qualitative pre-implementation surveys were conducted
prior to each small test of change. The data from the retrospective patient chart review
was used to quantify the total number of patients seen for uUTIs and to measure
prescribing rate of first-line agents.

Analysis

The rate of appropriately prescribing first-line agents for symptoms of uUTIs was
used to determine prescription adherence. The rate was computed as the number of
clinicians who adhered to prescribing first-line agents divided by the total number of
patients seen for uUTIs. Summary statistics (frequencies and percentages) were used to
quantify symptom reoccurrence. The retrospective review of data from October 25, 2021,
through December 2, 2020, was used to measure these outcomes. A chi-square analysis
would have been used to determine whether any significant increase in adherence to
prescribing first-line agents to treat uUTIs in PrMNPW occurred after the proposed small
test of change was implemented.
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Initial reviews found that clinicians at Athena Med-Monterey used guidelines and
resources referring to the 2011 IDSA guidelines. These resources guided them in
prescribing first-line agents for treating uUTI. Therefore, no quality improvement
intervention was needed; setting the clinic’s practice guidelines for treating uUTI would
have been futile.

Two qualitative pre-implementation surveys were conducted prior to each small
test of change. The first face-to-face semi-structured interview was conducted in the first
phase on November 4, 2020, before the intended timeline for establishing clinical
guidelines. This initial, qualitative pre-implementation survey identified two themes:
resources clinicians referred to for antibiotic prescription decisions, and tailoring
antibiotic treatments according to urine culture results in accordance with guidelines. The
answers to the survey halted the small test of change and prompted the next phase of
attempted practice change. The second face-to-face semi-structured interview was
conducted on January 30, 2021, and was used to plan the second small test of practice
change. The survey evaluated the clinicians’ practices and perceptions of performing
urine cultures for AUC.

Ethical Considerations

This project was guided by the American Nurses Association (2015) Code of
Ethics with Interpretive Statements. It was also guided by the Jesuit values (University of
San Francisco, 2001) of protecting, promoting, and optimizing health and abilities,
preventing illness, alleviating suffering through the human response to diagnosis and
treatment, and advocating for the care of the individuals and populations served. By
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promoting use of clinical practice guidelines based on evidence , the study aimed to guide
clinicians to choose first-line agents for treating uUTI in women, thereby preventing
unnecessary use of antibiotics in treating such infections. Decreasing the prevalence of
antibiotic resistance applies the principle of nonmalefience (i.e., do no harm), a nursing
duty to protect patients’ safety.
Every effort was made to protect the patients’ privacy and rights and to respect
and promote each person’s dignity. The aggregation of data for this project did not
contain any patient information and was stored on a locked computer with two-factor
authentication. The data were destroyed four months after the project was completed.
This project was approved by the University of San Francisco’s Doctor of Nursing
Practice program as a quality improvement project not requiring review by the
Institutional Review Board (Statement 1).

Results
The evaluation of clinicians’ adherence to evidence-based clinical practice guidelines for
the treatment of uUTI in PrMNPW was successfully completed using the small test of change
process in the first phase of the three-year proposed intervention. The PDSA method guided the
small test of change. The evaluation of clinicians’ adherence to prescribing first-line, or
alternative agents, and symptom resolution at 28 days post-uUTI treatment were also
successfully completed. This first phase was initiated on October 21, 2020 and was completed on
January 1, 2021, with planned quality practice improvement aimed to establish evidenced-based
clinical guidelines for treating uUTI in PrMNPW. The change agents performed the qualitative
pre-intervention survey on November 4, 2020, and initiated the retrospective chart review on
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October 28, 2020. Findings of both the qualitative interview and retrospective chart review were
reviewed on December 5, 2020, and these findings guided the decision to abandon the first
planned quality improvement intervention.
The change agents then decided to continue the retrospective chart review until January
1, 2021, to collect more data to measure the following: use of evidenced-base clinical guidelines
or references, such as the 2011 IDSA guidelines; adherence to the evidence-based guidelines as
measured by prescription of first-line agents for uUTI; and practice outcomes as measured by no
symptom recurrence within 28 days post-treatment.
All eight prescribing clinicians participated in the structured pre-intervention survey. The
face-to-face in-office interviews were scheduled in advanced and recorded on paper by the
APNS. Out of eight of the prescribing clinicians at Athena Med-Monterey, 6 (75%) were
obstetricians and gynecologists; one was a general medicine doctor, and one was an APN. The
pre-intervention clinician survey identified guidelines that the clinicians referred to for treating
uUTIs. All eight (100%) of the clinicians used the resource applications UpToDate, Medscape,
and Athena Med’s Epocrates. The review found that these electronic resource applications refer
to the 2011 IDSA guidelines for treating uUTI.
The qualitative assessment questions revealed that all eight (100%) of the prescribing
clinicians strongly agreed that other clinicians prescribing in their absence would prescribe firstline agents for treating AUC in PrMNPW, in accordance with guidelines. Furthermore, all eight
(100%) strongly agreed that clinicians prescribing in their absence would prescribe antibiotics
according to urine culture results when treating uUTI, in accordance to guidelines, and all eight
(100%) strongly agreed that clinicians prescribing in their absence would start, stop, or tailor
antibiotic treatment according to urine culture results and guidelines for treating uUTI. The pre-

28
intervention survey also found that all eight (100%) of the clinicians ordered urine cultures for
AUC symptoms.
Data from September 25, 2020 to January 1, 2021 were collected for retrospective chart
review. The data were used to measure the rate of adherence to prescribing first-line agents,
measure the rate of adherence to not performing urine cultures for AUC, and quantify the
number of patients who had uUTI symptom recurrence within 28 days post-treatment. A total of
seven PrMNPW with documented symptoms of uUTI were seen. Their ages ranged from 18–47
years old. Urine dipstick was performed for five (71%) of the seven patients, and urine cultures
were performed for all (100%) seven patients. Of the patients who did not receive urine dipstick,
two (29%) were seen via telehealth; therefore, urine dipstick could not be performed. All seven
(100%) were treated for uUTIs in accordance with the 2011 IDSA guidelines. Four (57%) were
appropriately prescribed first-line or alternative agents, and three (43%) were not prescribed
antibiotic agents as indicated by urine culture results. No symptom recurrences were noted at 28
days post antibiotic treatment. Furthermore, no cases of pyelonephritis were seen.
Discussion
Summary
The small test of practice change using the PDSA method demonstrated success in
implementing a structured and inexpensive provider-driven process for evaluating adherence to
evidence-based clinical practice guidelines at Athena Med-Monterey, a multi-provider primary
care organization. Both qualitative assessment and retrospective chart review found that the
clinicians at Athena Med-Monterey maintained consistent behaviors of using evidenced-based
guidelines and adhered to prescribing first-line and alternative agents for treating uUTI in
PrMNPW. No quality practice improvement intervention was needed, and the plan to establish
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clinical treatment guidelines for uUTI was abandoned. The clinicians’ utilization of guidelines
results in positive practice and treatment outcomes. The clinicians at Athena Med-Monterey are
comfortable other clinicians, on his/her behalf, prescribe a first-line agent for the treatment of
uUTI. The retrospective chart review also revealed that the clinicians’ adherence to prescribing
first-line and alternative agents resulted in no symptom recurrence 28 days post-treatment.
The FNP led the quality improvement process using the small test of change and PDSA
method, the TTM of behavior, and the clinic’s EHRs. This quality improvement intervention was
carried out over a three-month period. The intention to improve the quality of practice was
planned, trialed, evaluated, and acted upon. The TTM was used to predict and guide the
clinicians’ expected behaviors to trial the quality improvement intervention. The qualitative
assessment and retrospective chart review were used to measure practice behavior and outcomes.
Interpretations
The findings aligned with the trials, systematic reviews, and meta-analyses conducted
after the CDC’s 2017 review of the 2011 IDSA guidelines (Table 1). Clinicians who referenced
evidence-based guidelines to manage uUTIs were most likely to prescribe first-line agents and
yield desired patient outcomes in terms of bacterial and symptom resolution as well as costeffectiveness. The use of EHRs and resource applications, such as UpToDate, Medscape, and
Athena Med’s Epocrates, influenced this quality practice at Athena Health. Real-time patient
information and updated resource applications supported efficient and well-informed electronic
prescription capabilities, and retrospective chart review (through EHRs) was also a cost-saving
process for measuring quality practice outcomes.
The TTM’s stages of behavioral change occurred among the clinicians at Athena MedMonterey when evaluating the clinical practice and implementing processes to further improve
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practice quality. Although no intervention was needed to change the current practice for treating
uUTIs in PrMNPW, the motivation to improve and evaluate the current practice triggered
behavioral changes. Four stages of behavior changes were observed during the initial phase of
the three-year project proposal:
1. Stage 1: The clinicians were aware of the need to evaluate the practice and practice
outcomes but had no thought of adopting evaluation tools or processes.
2. Stage 2: The clinicians acted on their decision to trial the small test of change and the
PDSA processes for evaluating and improving the practice.
3. Stage 3: The clinicians maintained their behavior of using current evidenced-based
references when treating uUTIs in PrMNPW.
4. Stage 4: The clinicians acted on a decision to abandon the planned practice improvement.
They are yet to decide whether to adopt a further small test of change and PDSA
processes to continue quality improvement.
Both the qualitative assessment and the retrospective chart review found that clinicians at Athena
Med-Monterey were consistent in using evidenced-based clinical guidelines and prescribing
first-line agents for treating uUTI in PrMNPW. How and when this behavior change occurred
was not assessed in this project.
Consistent utilization of evidence-based guidelines could advance adherence to
prescribing first-line agents for treating uUTI in PrMNPW, specifically in a multi-provider
primary healthcare organization. The small test of practice change using the PDSA method could
be used to establish processes to evaluate and promote the use of evidence-based clinical
guidelines and the use of first-line agents for treating other uncomplicated infections commonly
seen in primary care, such as respiratory and skin infections. Clinicians at Athena Med-Monterey
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will consider the possibility of adopting a small test of change and PDSA processes for other
potential practice improvement in antibiotic prescribing.
Limitations
Although uUTI are also common in women older than 50 years, this project only
examined quality improvement for treating uUTIs in PrMNPW aged 18–50 years. Treatment
guidelines for uUTIs in postmenopausal women were not included in the 2011 International
Clinical Practice Guidelines for the Treatment of AUC and Pyelonephritis published by the
IDSA and the European Society for Microbiology and Infectious Diseases.
Given the limitations surrounding healthcare during the COVID-19 pandemic, physical
examinations and in-clinic urine dipstick tests were infeasible. Review of symptoms was
performed through telehealth for two of the seven cases included in the retrospective chart
review, and urine collection for culture was carried out in a laboratory (vs. clinic-performed
urine dipstick). Also, local susceptibility information was unavailable, which limited the use of
SMX-TMP as a first-line antibiotic choice for treating AUC.
As previously mentioned, both the qualitative assessment and the retrospective chart
review found that clinicians at Athena Med-Monterey used evidenced-based clinical guidelines
and first-line agents for treating uUTIs in PrMNPW. Since no practice change intervention
occurred, pre- and post-intervention comparison was not conducted. Additionally, quality
measurement tools were not available for comparing and quantifying the clinic’s practice
outcomes.
The 2011 IDSA and 2017 CDC guidelines do not recommend performing urine cultures
when treating AUC. Thus, not performing urine cultures is considered adherence to evidenced-
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based guidelines. This project attempted to measure this adherence, but limited access to EHRs
did not allow for this small test of practice change.
Conclusion
uUTIs are diagnosed and managed in primary healthcare. To control for antibiotic
resistance and reduce antibiotic use, the small test of practice change using the PDSA method
could be used to establish processes to evaluate and promote the use of evidence-based clinical
guidelines in a multi-provider organization like Athena Med-Monterey. Consistent utilization of
evidence-based guidelines advances adherence to prescribing first-line agents, improves the
quality of clinical decisions, allows for the delivery of consistent care, and yields high-quality
patient outcomes when treating uUTIs in PrMNPW. Therefore, this project recommends these
APN-driven processes to promote the use of evidenced-based practice guidelines and first-line
agents for the treatment of other uncomplicated infectious conditions seen in primary care, such
as uUTIs in post-menopausal women and respiratory and skin infections.
Funding
This project received no external funding.
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Statement 1
DNP Statement of Non-Research Determination Form

Student Name: Ira Amayun_____________________________________
Title of Project:
A Quality Improvement Project: Utilizing Clinical Practice Guidelines for Women
Presenting with Symptoms of Uncomplicated Urinary Tract Infections

Brief Description of Project:
A) Aim:
The overall goal of the proposed project is to promote adherence to evidence-based
guidelines for treating uncomplicated urinary tract infections (uUTIs) for
premenopausal non-pregnant women.
B) Description of Intervention:
The proposed project will use the 2011 IDSA clinical practice approach for treating
uUTIs in pre-menopausal non-pregnant women, as well as the clinicians’ practice
preferences, to set or modify practice guidelines. The plan-do-study-act method will be
used to guide the small tests of practice change.
C) How will this intervention change the practice?
The proposal will examine whether integrating the 2011 IDSA approach into a primary
clinic’s current uUTI management practices (vs. the clinic’s current practices alone)
will increase adherence to evidence-based guidelines and evaluate opportunities to
improve the quality of clinical decisions and patient outcomes over a few weeks’ series
of small tests of change.
C) Outcome measurements:
The following measures could be used to evaluate the proposal’s outcomes:
1. Clinicians who prescribed antibiotics in the four weeks after the implementation
of the small tests of change referenced the clinical practice guidelines in the
treatment of 80% of all the PrMNPW seen with UTI symptoms.

38
2. Out of all the PrMNPWs seen with UTI symptoms in the four weeks after the
implementation of the small tests of change, 80% are prescribed the appropriate
first-line agents for AUC.
3. Out of all the PrMNPWs seen with UTI symptoms in the four weeks after the
implementation of the small tests of change, 80% are prescribed the appropriate
first-line agents for acute pyelonephritis.
This proposal will also attempt to quantify improvement in the quality of clinical
decisions using clinical practice guidelines and measure symptom resolution at 28 days
post uUTI treatment.

To qualify as an evidence-based change in practice project, rather than a research project, the
following criteria outlined in federal guidelines will be used
(http://answers.hhs.gov/ohrp/categories/1569):

☐ This project meets the guidelines for an evidence-based change in practice project as
outlined in the project checklist (attached). Students may proceed with implementation.

☐

This project involves research with human subjects and must be submitted for IRB approval
before project activity can commence.
Comments:
EVIDENCE-BASED CHANGE OF PRACTICE PROJECT CHECKLIST *
Instructions: Answer YES or NO to each of the following statements:
Project Title:
The aim of the project is to improve the process or delivery of care with
established/accepted standards or to implement evidence-based change. There is no
intention of using the data for research purposes.
The specific aim is to improve performance on a specific service or program and is
a part of usual care. ALL participants will receive standard care.
The project is NOT designed to follow a research design (e.g., hypothesis testing
or group comparison, randomization, control groups, prospective comparison
groups, cross-sectional, case control). The project does NOT follow a protocol that
overrides clinical decision-making.
The project involves the implementation of established and tested quality standards
and/or systematic monitoring, assessment, or evaluation of the organization to
ensure that existing quality standards are being met. The project will NOT develop
paradigms, untested methods, or new untested standards.
The project involves the implementation of care practices and interventions that are
consensus-based or evidence-based. The project does NOT seek to test an
intervention that is beyond current science and experience.

YES
X

X
X

X

X

NO

39
The project will be conducted by the staff where the project will take place and
involves staff who are working at an agency that has an agreement with USF
SONHP.
The project has NO funding from federal agencies or research-focused
organizations and is not receiving funding for implementation research.
The agency or clinical practice unit agrees that this is a project that will be
implemented to improve the process or delivery of care, i.e., not a personal
research project that is dependent upon the voluntary participation of colleagues,
students, and/or patients.
If there is an intent to, or possibility of publishing your work, you and supervising
faculty and the agency oversight committee are comfortable with the following
statement in your methods section: “This project was undertaken as an evidencebased change of practice project at X hospital or agency and as such was not
formally supervised by the Institutional Review Board.”

X

X
X

X

ANSWER KEY: If the answer to ALL of these items is yes, the project can be considered an
evidence-based activity that does NOT meet the definition of research. IRB review is not
required. Keep a copy of this checklist in your files. If the answer to ANY of these questions
is NO, you must submit for IRB approval.
*Adapted with permission of Elizabeth L. Hohmann, MD, Director and Chair, Partners Human
Research Committee, Partners Health System, Boston, MA.

STUDENT NAME (Please print): Ira Amayun
_______________________________________________________________________
Signature of Student:
______________________________________________DATE: Oct. 31, 2020____

_

SUPERVISING FACULTY MEMBER (CHAIR) NAME (Please print):
___Dr. Alexa Curtis______________________________________________________
Signature of Supervising Faculty Member (Chair):
______________________________________________DATE_______________
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Table 1
Synthesis Table
Study

Design

Sample

Outcomes/Findings

Qualitative analysis of
PCPs’ prescribing decisions
for urinary tract infections

Qualitative semistructured interviews and
thematic analysis

Eighteen PCPs practicing in two
family medicine clinics in a large
urban area in Texas between July
2017 and November 2017

Few providers relied on the IDSA
guidelines for treating uUTIs.

Retrospective cohort study
of Medicare Part B
enrollees in New York
State

There were 23,981 and 26,677
prescriptions written for cystitis
across New York State in 2016 and
2017, respectively.

SMX-TMP, fosfomycin, and Blactamase prescriptions increased, and
FQ use decreased in older female and
male adults.

Grigoryan et al. (2019)
Antibiotic prescribing in
New York State Medicare
Part B beneficiaries
diagnosed with cystitis
between 2016 and 2017

The results suggested that the
widespread prevalence of FQ and Blactamase prescriptions necessitates
outpatient antimicrobial stewardship.

Yu et al. (2020)

Preferential use of NTF
over FQ for AUC and
outpatient E. coli resistance
in an integrated healthcare
system

Retrospective preintervention postintervention study

Retrospective study

Women aged 19–64 years old were
seen at five family medicine clinics
and prescribed NTF, ciprofloxacin,
or levofloxacin for uncomplicated
cystitis.

Of the 567 women included in this
study, 395 were given NTF, and 172
were given FQ; 343 (86.8%) and 18
(10.5%) were appropriately prescribed
NTF and FQ, respectively. Of the
women who were inappropriately
prescribed FQ, 15 (87.8%) lacked
contraindication to NTF.

Quasi-experimental study

Women aged 18–64 years old who
were prescribed NTF, SMX-TMP,
or ciprofloxacin within seven days
of encounters at five family
medicine clinics

Clinics that received education
increased adherence from 22.1% to
58.8% (p < 0.01). Revising/adding
default prescription instructions to
targeted antimicrobials and DOT, and
staff in-service increased clinician
adherence to uncomplicated cystitis
first-line antibiotic DOT guidelines.

Robinson et al. (2019)

Improvement in adherence
to antibiotic duration of
therapy recommendations
for uncomplicated cystitis:
A quasi-experimental study
Giancola et al. (2019)

After a change in institutional
guidelines, there was an immediate 26%
reduction in FQ use and stabilization of
FQ-resistant E. coli. NTF use increased
without any change in NTF resistance.

This study included 5,714 adults
treated for acute cystitis and 11,367
outpatient E. coli isolates.

Pedela et al. (2017)

Evaluation of the trends and
appropriateness of FQ use
in the outpatient treatment
of AUC at five family
practice clinics

An urban setting in Colorado, a 477bed hospital, an emergency
department, an urgent care
department, eight community health
clinics, and 15 school-based clinics
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Diagram 1
Reviews based on Prisma Diagram

PRISMA 2009 Flow Diagram©
Criteria: Literature in English, published between 2017 and February 21, 2020, meeting medical
search terms.

Identification

Cochrane
https://www.cochranelibrary.com/advanced-search

PubMed
https://pubmed.ncbi.nlm.nih.gov/
(n = 31)

(n = 25)
Records excluded
(n =18)
Records after duplicates removed

Screening

n56- 19duplicates = 37
(n = 37)

2 recurrent cystitis
1 green tea treatment
1 kidney transplant
3 pregnant women
1 cefditoren pivoxil

Records screened
n=37
(n = )

1 uroprofit, chronic cystitis
1 phytotherapeutic med
1 overactivity/incontinence
1 mecillinenam

Eligibility

1 complicated cystitis (DM)

Full-text articles assessed
for eligibility
(n=19)

Full-text articles excluded,
1 article not available

with reasons
(n = 8)

4 no full text available
1 Not specific to prescribing first-line
antibiotics.
1 Cepodoxime study

Included

Studies included in
synthesis
4 quantitative
1 qualitative
(n = 5)

1 recurrent infection and MDR
1 Urine culture cost effectiveness
1 Generic vs brand name antibiotics
1 pharmacokinetics of
nitrofurantoin
1 Guideline review
1 Guideline Update
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Table 2
Gap Analysis
Focus Area

Current
Situation

Desired Situation

Use of clinical practice
guidelines, such as the
2011 IDSA, in the
treatment of uUTIs.

No available data

Use of the 2011 IDSA
approach to uUTI
treatment is evident
and available for
reference.

Gap Factor/
Deficiency
No available data

Action Plan
Perform clinician survey.
The 2011 IDSA approach to
AUC treatment is available for
reference. This may be
modified according to survey
results and according to the
PDSA method to reflect what
would work with the current
practice.

A diagram of the 2011
IDSA approach to
uUTI treatment is
available for clinicians
to reference.

PrMNPWs with
symptoms of AUC are
prescribed appropriate
first-line agents in
accordance with the
2011 IDSA guidelines.

No data

PrMNPWs with
symptoms of AUC
will be prescribed
appropriate first-line
agents in accordance
with the 2011 IDSA
guidelines.

No available data

Recommend use of clinical
practice guidelines and quality
measurement tools and/or
evaluation process.

PrMNPWs with
symptoms of acute
pyelonephritis will have
their urine sent for
culture in accordance
with the 2011 IDSA
guidelines.

No data

Clinicians wait for
urine culture results
and prescribe first-line
agents in accordance
with the 2011 IDSA
guidelines.

No available data

Recommend use of clinical
practice guidelines and quality
measures.

Patients with uncertain
diagnoses will have
their urine sent for
culture to confirm
antibiotic treatment.

No data

Patients with uncertain
diagnoses will have
their urine sent for
culture to confirm
antibiotic treatment.

No available data

Continue practice.

PrMNPW treated for
symptoms of uUTI
report symptom relief
within 48 hours after
being seen at the clinic,
and symptom resolution
at 28-days post uUTI
treatment.

No data

Patients report
symptom relief within
48 hours after being
seen at the clinic or
symptom resolution at
28-days post-uUTI
treatment.

No available data

Recommend use of quality
measurement tools and/or
evaluation process.
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Table 3
Timeline (Gantt Chart)
Year 1 Tasks
Formation of one clinician team for a
small test of change using the PDSA
method

Sept

Oct

Nov

Dec

Jan

Feb

Mar

Apr

May

Jun

Jul

Oct

Nov

Dec

Jan

Feb

Mar

Apr

May

Jun

Jul

Aug

Aug

Four-week retrospective chart review of
the target population treated for UTI
symptoms
Integration of the 2011 IDSA Approach
to uUTI Treatment into the clinic’s
current practices
Initial small test of change begins
Use of the PDSA method
Initial small test of change evaluation
Plan second small test of change
Outcome measurement and report
Full implementation
First-year post-implementation survey
Report distribution

Year 2 Tasks
Full implementation of the PDSA
method
Outcome measurement and report
Second-year post-implementation
survey
Outcome measurement and report
Report distribution

Sep
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Year 3 Tasks
Full implementation of the PDSA
method
Outcome measurement and report
Third-year post-implementation survey
Outcome measurement and report
Report distribution

Oct

Nov

Dec

Jan

Feb

Mar

Apr

May

Jun

Jul

Aug

Sep
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Figure 1
Urine Culture Smart Phrase Box
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Table 4
Small Test of Change Work Breakdown Structure
Project clinic leadership: Allied Health Education Director
Change agents: APN and APNS
Participants: All of the clinic’s prescribing clinicians

Responsible (R): Member is responsible for completing the task
Consulted (C): Member was communicated with regarding the decision and task
Informed (I): Member was updated on decisions and actions

Role
Project Leader

APN and FNP student

Deliverable/Activity
Initialization Phase
Review the 2011 IIDSA Approach to uUTI Treatment vs Athena
Med-Monterey clinicians’ resource/guidelines

I/C

R

Planning Phase
Perform a four-week retrospective chart review of the target
population treated for UTI symptoms.

I/C

R

I

R

Evaluation and Assessment Phase
Analyze and report outcomes to the medical director.

I

R

Review Phase
Create lessons learned.

I

R

Make the decision to continue or terminate the initiative.

R

I

Create a project closure report and present recommendations.

I/C

R

Print and laminate the modified approach diagram and place it in
a visible position for reference.
Staff in-service sessions given prior to implementation.
Implementation Phase of the Small Test of Change
Prescribers refer to guidelines.
Conduct the PDSA method in cycles as needed for the desired
quality practice.
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Table 5
Responsibility/Communication Matrix
Communication

Method

Frequency

Goal

Owner

Audience

Project Plan

Face-toface
meeting,
clinic or
university
email

Once

Present project
for approval and
planning

Clinic
leadership
and change
agents
(APN,
APNS)

Project
leader and
champions
(APN,
FNP
student)

Review of
clinic
guidelines vs.
evidencedbased
guidelines
(2011 IDSA)

Face-toface
meeting

Once at first
phase of
implementation,
and initiation of
small test of
change

Present study
results of the
clinicians’
adherence to
evidence-based
practice for
treating uUTIs

Change
agents
(APN,
APNS)

Project
leader and
champions
(APN,
FNP
student)

Project status

Face-toface
meeting,
university
email

Weekly

Review project
status using the
PDSA method
and plan next
steps for small
test of change

Clinic
leadership
and change
agents
(APN,
APNS)

Project
leader and
champions
(APN,
FNP
student)

Project review
and analysis

Face-toface
meeting,
university
email

Monthly

Review and
present
outcomes and
analysis of
small test of
change

Clinic
leadership
and change
agents
(APN,
APNS)

Project
leader and
champions
(APN,
FNP
student)

Project update
and next steps

Face-toface
meeting
and
university
email

After each
small test of
change
evaluation

Present reviews,
outcomes, and
next small test
of change until
desired practice
improvement

Project
leader and
champions
(APN,
APNS)

Project
leader and
champions
(APN,
FNP
student)
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Figure 2
The Organization’s Strengths, Weaknesses, Opportunities, and Threats (SWOT)

Strengths
Weaknesses
Clinic has a fast and reliable EHR system.
Multi-provider organization
Clinic performed dipstick and urine culture and sensitivity tests
and received results within 48-72 hours through the EHRs
Accessible resource applications (UpToDate, Medscape,
Epocrates) in EHR

Antibiogram is currently unavailable to
support clinical decision-making.
Measurement tools are currently
unavailable to quantify quality care.

Efficient collaborations among clinicians through clinic emails and phone system

Opportunities

Threats
Use of quality measures to evaluate practice and
treatment outcomes
Culture is supportive of practice change for
improvement

Constraints in clinicians' time and schedules
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Table 6
Estimated Three-Year Budget
Breakdown

Revenue

Expenses

Expenses

Expenses

2021

2022

2023

Training venue

Training room

Training room
already available

$0

$0

$0

Materials

4 copies of the
clinical guidelines

$15
(Office supplies
available)

$15

$0

$0

$200
(Indirect care from
education and
training fund)

$200

$0

$0

$800
(Indirect care from
education and
training fund)

$800

$0

$0

$2000
(Graduate fee
fund)

$2000

$0

$0

$3000
graduate fee,
quality
improvement and
staff training fund

$1000

$1000

$1000

$8,015
3-year revenue for
2021, 2022, and
2023

$6,015
Year 2021
expenses

$1000
Year 2022
expenses

$1000
Year 2023
expenses

Training cost for each
of the eight clinicians

Training cost:
Clinician
leader/graduate
student

Data collection and
analysis by clinician
leader/graduate
student

4 laminated sheets of
the uUTI treatment
approach
15 minutes in-service
for each of the three
clinicians
(for $100/hour
salary)
8 hours collaboration
with Medical
Director and eight
clinic providers

80 hours or 10 days
at $25/hour graduate
student fee
Retrospective chart
review (remote
EHRs)

Quality measures
analysis, report, and
distribution by
clinician
leader/graduate
student

40 hours or 5 days
(3 months and yearly
post implementation)
Chart review (remote
EHRs)
Report presentation

TOTAL
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Deliverable 1
First Pre-implementation Clinician Survey
A. Questions:
1. I use the ________ clinical practice guidelines in the treatment of uncomplicated urinary tract
infections.
2008 ACOG (The American College of Obstetricians and Gynecologists)
2017 CDC (Centers for Disease Control and Prevention)
2011 IDSA (Infectious Disease Society of America)
Athena Clinical Guidelines
App-based Resources:
UpToDate
Epocrates
Medscape
Other(s): ___________________________
2. I feel comfortable that the clinicians prescribing in my absence:
a. Choose first-line agents in the treatment of uncomplicated cystitis according to the
guidelines I use.
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
b. Choose appropriate antibiotics for treating uncomplicated pyelonephritis once urine
culture and sensitivity results are known and in accordance with the guidelines I use.
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
c. Start, stop, or tailor antibiotic treatment according to urine culture results and according
to guidelines I use for treating uncomplicated urinary tract infections.
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
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Deliverable 2
Second Pre-implementation Clinician Survey

1. I know the differences in symptoms between AUC and pyelonephritis according to the
2011 IDSA and the 2017 CDC guidelines.
Strongly agree
Agree
Somewhat agree
Disagree
Strongly disagree

2. I order urine cultures to treat AUC at the day of clinic visit, before the first dose of
antibiotics.
All the time
Often
Half the time
At times
Never

3. I feel confident in prescribing first-line agents for treating AUC without performing urine
cultures.
Strongly agree
Agree
Somewhat agree
Disagree
Strongly disagree
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Figure 3
PDSA Method and Data Collection Tool
What are we trying to accomplish?
Promote adherence to evidenced-based
clinical practice guidelines

How will we know that a change is an
improvement?
Evaluate current practice and outcomes
(qualitative and retrospective)
What changes can we make that will
result in improvement?
Implement small test of practice change

Plan:
Act:
Abandon, adapt, or
adopt practice change

Integrate evidencebased clinical practice
guidelines for the
treatment of
uncomplicated UTI

Do:
Study:
Analyze intervenion
and practice
outcomes

Evaluate current
practice and
outcomes (qualitative
and retrospective)

Implement small test
of practice change

